Table 3 Factors associated with receiving triage among HPV screen positive women in Nicaragua in 2017
From: HPV-based cervical cancer screening in Nicaragua: from testing to treatment
| Not Triaged (N = 3120) | Triaged (N = 3656) | ||||
|---|---|---|---|---|---|
| n (%) | n (%) | Unadjusted Prevalence ORa (95% CI) | Adjusted Prevalence ORb (95% CI) | Triage Ratio | |
| Province | |||||
| Carazo | 1062 (54.1) | 900 (45.9) | Ref | Ref | Ref |
| Chinandega | 1482 (48.9) | 1546 (51.1) | 1.23 (1.10–1.38)* | 1.23 (1.09–1.38)* | 1.11 |
| Chontales | 576 (32.3) | 1210 (67.8) | 2.48 (2.17–2.81)* | 2.78 (2.43–3.19)* | 1.48 |
| Age, years | |||||
| < 30 | 28 (50.0) | 28 (50.0) | Ref | Ref | Ref |
| 30–39 | 1812 (46.3) | 2103 (53.7) | 1.16 (0.68–1.97) | 1.18 (0.69–2.02) | 1.07 |
| 40–49 | 747 (43.3) | 979 (56.7) | 1.31 (0.77–2.23) | 1.36 (0.79–2.34) | 1.13 |
| 50–59 | 512 (49.2) | 528 (50.8) | 1.03 (0.60–1.77) | 1.07 (0.62–1.86) | 1.02 |
| 60+ | 19 (54.3) | 16 (45.7) | 0.84 (0.36–1.96) | 0.89 (0.38–2.11) | 0.91 |
| Unknown | 2 (50.0) | 2 (50.0) | 1.00 (0.13–7.60) | 0.63 (0.08–4.97) | 1.00 |
| HPV Screening Modality | |||||
| Self-collected | 3019 (45.9) | 3559 (54.1) | Ref | Ref | Ref |
| Provider-collected | 27 (24.1) | 85 (75.9) | 2.67 (1.73–4.13)* | 2.82 (1.82–4.39)* | 1.40 |
| Unknown | 74 (91.9) | 12 (14.0) | 0.14 (0.07–0.25)* | 0.07 (0.04–0.14)* | 0.26 |
